期刊文献+

三维适形放疗与改良半胸照射放疗治疗弥漫性恶性胸膜间皮瘤的比较研究 被引量:3

Results of flexible 3D-conformal radiotherapy for patients with diffuse malignant pleural mesothelioma and comparative study of this technique with conventional radiotherapy
下载PDF
导出
摘要 目的:弥漫性恶性胸膜间皮瘤治疗以手术和化疗为主,放疗常规采用半胸照射的技术,因肺损伤较大,使得放疗在弥漫性恶性胸膜间皮瘤治疗中的价值不明确。我们采用X射线三维适形放疗(3DCRT)加电子线野灵活布野的模式治疗8例弥漫性恶性胸膜间皮瘤,观察其近期疗效和放射损伤,并模拟改良的常规半胸照射放疗的方法,比较两种技术的肺损伤大小。方法:自2004年1月~2007年11月,我院收治的8例弥漫性恶性胸膜间皮瘤,其中5例为多程化疗失败者,3例为单纯放疗。化疗方案为GP、NP、TP和培美曲塞+卡铂,放疗采用X射线三维适形放疗和电子线野灵活布野的治疗模式,按常规分割的方式给予总量32.2~64.0Gy照射。同时模拟常规半胸照射放疗的技术,采用TPS系统模拟并计算肺的V20、V30和平均肺受量(MLD),与三维适形放疗和电子线野灵活布野的治疗模式相比较。结果:8例患者放疗后,1例患者达CR,其余患者均达PR。随访至2008年2月,2例患者死亡,其余6例均存活,平均生存时间为15.4个月。采用化疗+放疗者平均生存时间为18.8个月,单纯放疗组为9.7个月。采用三维适形放疗加电子线野灵活布野的治疗模式8例患者的平均V20为20.5%,V30为15.6%,患侧肺MLD为18.8Gy,健侧肺MLD2.2Gy。模拟常规半胸照射放疗技术8例患者的平均V20为36.8%,V30为27.9%,患侧肺MLD为31.1Gy,健侧肺MLD1.2Gy。两种技术的肺V20、V30和患侧肺MLD均存在差异,显示三维适形放疗加电子线野灵活布野的治疗模式可能有降低正常肺照射剂量的趋势;健侧肺MLD两者无明显差异。采用三维适形放疗加电子线野灵活布野治疗模式的8例患者均出现1~2度放射性肺炎。根据治疗前和治疗后生活质量评估显示治疗后的生活质量由治疗前的平均2.83上升为3.76,生活质量有所改善。结论:弥漫性恶性胸膜间皮瘤对放疗有一定的敏感性,采用三维适形放疗加电子线野灵活布野治疗模式是可行的,较改良的常规半胸照射放疗方式为佳,与相关文献相比较生存期无下降,但肺损伤明显减少,患者的生活质量有所改善。 Objective:Patients with diffuse malignant pleural mesothelionm (MPM) are mainly treated with surgery. Hemithoracic conventional radiotherapy (CRT) was mostly used for postoperative propose, and its severe radiation pneumonitis leads to the uncertainties of radiation in MPM treatment. New technique of flexible 3D-conformal radiotherapy (3DCRT) with combination of photon and electron is used in our study MPM and the comparative study of flexible 3DCRT and CRT was pursued to explore the possibility of radiation pneumonitis. Methods:From Jan. 2004 to Oct. 2007, 8 patients with MPM were treated with flexible 3DCRT. Five patients had received cycles of chemotherapy and 3 were treated with 3DCRT alone. New technique of flexible 3DCRT with combination of photon and electron was used in our study,and DT 32.2-64. 0Gy with conventional split were delivered. CRT technique was mimicked to compare with 3DCRT technique to explore the possibility of lung damage in two methods. Results:One patient reached CR and other 7 patients got PR after radiation. Two patients died during the follow-up. The median survival time (MST) was 15.4months and it was 18. 8months for sequential chemotherapy and radiotherapy group and 9.7months for radiotherapy alone. The V20, V30, ipsilateral and contralateral median lung dosage(MLD) was 20. 5% , 15.6% , 18.8Gy and 2. 2Gy respectively when the flexible 3DCRT technique was used, whereas it was 36. 8% , 27. 9%, 31. 1Gy and 1.2Gy respectively when the CRT technique was used. Values of the lung V20, V30 and ipsilateral MLD for the flexible 3DCRT technique were much less than those for the CRT technique, whereas there was no difference for the contralateral MLD between the two techniques. All patients received radiation were found to have lung fibrosis and were classified as grade 1-2 radiation pneumonitis. The quality of life was increased from score 2. 83 to 3.76. Conclusion: MPM is moderately sensitive to radiation. The flexible 3DCRT technique is feasible in the treatment of MPM and lung damage is reduced apparently comparing with the CRT technique. The quality of life of patients with MPM is improved after irradiation.
出处 《临床肿瘤学杂志》 CAS 2008年第9期828-831,共4页 Chinese Clinical Oncology
关键词 弥漫性恶性胸膜间皮瘤 三维适形放射治疗 放射损伤 放射性肺炎 Diffuse malignant pleural mesothelioma 3DCRT Radiation damage Radiation pneumonitis
  • 相关文献

参考文献9

  • 1Yoshino I,Yamaguchil M, Yokamotu T, et al. Muhimodal treatment for resectable epithelial type malignant pleural mesothelioma [J]. World Journal of Surgical Oncology ,2004,2 ( 5 ) : 11.
  • 2Sugarbaker DJ,Flores R,Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and ceil type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients [ J]. J Thorac Cardiovasc Surg, 1999,117(1) :54 -65.
  • 3Rusch VW, Rosenzweig K,Venkatraman E, et al. A phase Ⅱ trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma [ J ]. Thorac Cardiovasc Surg, 2001, 122(4):788-795.
  • 4Ahamad A, Stevens CW, Smythe WR, et at. Intensity-modulated radiation therapy: A novel approach to the management of malignant pleural mesothelioma [ J ]. lnt J Radiat Oncol Biol Phys,2003,55 (3) :768 - 775.
  • 5Allen AM, Czerminska M, Janne PA, et al. Fatal pneomonitis associated with intensity-modulated radiation therapy for mesothelioma[ J ]. lnt J Radiat Oncol Biol Phys, 2006, 65 (3):640 - 645.
  • 6姚春萍,于金明,孙新东,李明焕.Ⅲ期非小细胞肺癌放射治疗射野累及器官的放射损伤研究[J].肿瘤防治杂志,2005,12(10):772-775. 被引量:2
  • 7Bottomley A,Gaafar R,Manegold C, et al. Short-term treatment- related symptoms and quality of life: Results from an international randomized phase Ⅲ study of eisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup study[J1. J Clin Oneol, 2006, 24(9):1435 -1442.
  • 8Ceresoli GL,Gridelli C, Santoro A. Muhidisciplinary Treatment of Malignant Pleural Mesothelioma [ J ]. Oncologist, 2007, 12 (7) :850 -863.
  • 9Weder W,Kestenholz P,Taverna C, et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma [ J ]. J Clin Oocol, 2004,22 ( 17 ) : 3451 - 3457.

二级参考文献9

  • 1于金明,郭守芳,李万湖,黄勇,尹莉萍,付政,李文武.非小细胞肺癌术前肺门纵隔淋巴结CT检查和术后病理结果比较的研究[J].肿瘤防治杂志,2003,10(12):1287-1289. 被引量:11
  • 2黎庶,马述盛,王天君,张景荣,赵惠儒,傅志民.CT诊断肺癌纵隔淋巴结转移判定标准的研究[J].中国医科大学学报,1995,24(2):193-195. 被引量:2
  • 3Cox J D , Stetz J , Paiak T F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)[J]. Int J Radiat Oncol Biol Phys, 1995,31(5):1341-1346.
  • 4WHO handbook for reporting results of cancer treatment[M]. Offset Publication No. 48. Geneva( Switzerland): World Health Organization, 1979.
  • 5Belderbos J S, Jaeger K D, Heemsbergen W D, et al. First resuits of a phase Ⅰ/Ⅱ dose escalation trial in non-small cell lung cancer using three-dimensional conformal radiotherapy[J]. Radiother Oncol, 2003,66(2):119-126.
  • 6Senan S, Burgers S, Samson M J, et al. Can elective nodal irradiation be omitted in stage Ⅲ non-small cell lung cancer? Analysis of recurrences in a phase Ⅱ study of induction chemotherapy and involved field radiotherapy [J]. Int J Radian Oncol Biol Phys,2002,54(4):999-1006.
  • 7Tsuiino K, Hirota S, Endo M, et al. Predictive value of dosevolume histogram parameters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancer[J]. Int J Radiat Oncol Biol Phys, 2003,55(1):110-115.
  • 8Hirota S, Tsujino K, Endo M, et al. Dosimetric predictors of radiation esophagitis in patients treated for non-small cell lung cancer with carboplatin/paclitaxel/radiotherapy[J]. Int J Radiat Oncol Biol Phys,2001,51(2):291-295.
  • 9Rosenman J G, Halle J S, Socinski M A, et al. High-dose conformal radiotherapy for treatment of stage Ⅲ a/Ⅲ b non-small cell lung cancer: technical issues and results of a phase Ⅰ/Ⅱ trial[J]. Int J Radiat Oncol Biol Phys,2002,54(2):348-356.

共引文献1

同被引文献43

  • 1Miles EF, Lanier NA, Kelsey CR, et al. Intensity-modulated ra-diotherapy for resected mesothelioma: The Duke experience [ J ]. Int J Radiat Oncol Biol Phys,2008, 71 (4) :1143-1150.
  • 2Krayenbuehl J, Oertel S, Davis JB, et al. Combined photon and electron three-dimensional conformal versus intensity-modulated radiotherapy with integrated boost for adjuvant treatment of malig- nant pleural mesothelioma after pleuropneumonectomy [ J ]. Int J Radiat Oncol Biol Phys,2007, 69 (5) : 1593-1599.
  • 3Krayenbuehl J, Dimmerling P, Ciernik IF, et al. Clinical outcome of postoperative highly conformal versus 3D conformal ra- diotherapy in patients with malignant pleural mesothelioma [ J ]. Radiat Oncol, 2014,9 : 32-37.
  • 4Weiss E, Siebers JV, Keall PJ. An analysis of 6-MV versus 18- MV photon energy plans for intensity-modulated radiation therapy (IMRT) of lung cancer[ J ]. Radiother Oncol, 2007, 82( 1 ) :55 -62.
  • 5Mackie TR, Holmes T, Swerdloff S, et al. Tomotherapy: a new concept for the delivery of conformal radiotherapy[ J ]. Med Phys, 1993,20(6) : 1709-1719.
  • 6Helou J, Clement CK, Sylvestre A, et al. Helical tomotherapy in the treatment of malignant pleural mesothelioma: The impact of low doses on pulmonary and oesophageal toxicity[ J:. Cancer Ra- diotherapy, 2013, 17(8) :755-762.
  • 7Lu SH, Cheng CH, Kuo SH, et al. Volumetric modulated arc therapy for nasopharyngeal carcinoma: a dosimetric comparison with TomoTherapy and step-and-shoot IMRT [ J 1. Radiother Oncol,2012, 104(3) :324-330.
  • 8Minatel E, Trovo M, Polesel J, et al. Tomotherapy after pleurec- tomy/decortication or biopsy for malignant pleural mesothelioma allows the delivery of high dose of radiation in patients with intact lung[ J]. J Thorac Oncol,2012,7(12) : 1862-1866.
  • 9Rosenzweig KE, Zauderer MG, Laser B, et al. Pleural intensity- modulated radiotherapy for malignant pleural mesothelioma [ J ]. Int J Radiat Oncol Biol Phys, 2012,83 (4) : 1278-1283.
  • 10Krayenbuehl J, Riesterer O, Graydon S, et al. Intensity- modulated radiotherapy and volumetric-modulated arc therapy for malignant pleural mesothelioma after extrapleural pleuropneumo- nectomy[ J]. J Appl Clin Med Phys,2013,14(4) :4130-4139.

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部